These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32691156)

  • 1. Evidence supporting the role of telomerase, MMP-9, and SIRT1 in attention-deficit/hyperactivity disorder (ADHD).
    Uzun Cicek A; Mercan Isik C; Bakir S; Ulger D; Sari SA; Bakir D; Cam S
    J Neural Transm (Vienna); 2020 Oct; 127(10):1409-1418. PubMed ID: 32691156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-inserted foreign body and attention-deficit/hyperactivity disorder: evaluated by the Conners' Parent Rating Scales-Revised.
    Özcan K; Özcan Ö; Muluk NB; Cingi C; Durukan K
    Int J Pediatr Otorhinolaryngol; 2013 Dec; 77(12):1992-7. PubMed ID: 24139587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum matrix metalloproteinase-9 levels and severity of symptoms in boys with attention deficit hyperactivity disorder ADHD/hyperkinetic disorder HKD.
    Kadziela-Olech H; Cichocki P; Chwiesko J; Konstantynowicz J; Braszko JJ
    Eur Child Adolesc Psychiatry; 2015 Jan; 24(1):55-63. PubMed ID: 24633733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Attention deficit/hyperactivity disorder: burden of the disease according to subtypes in recently diagnosed children].
    Escobar R; Hervas A; Soutullo C; Mardomingo MJ; Uruñuela A; Gilaberte I
    Actas Esp Psiquiatr; 2008; 36(5):285-94. PubMed ID: 18830848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetic and environmental contributions to attention deficit hyperactivity disorder as measured by the Conners' Rating Scales--Revised.
    Hudziak JJ; Derks EM; Althoff RR; Rettew DC; Boomsma DI
    Am J Psychiatry; 2005 Sep; 162(9):1614-20. PubMed ID: 16135619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The usefulness of Conners' Rating Scales-Revised in screening for attention deficit hyperactivity disorder in children with intellectual disabilities and borderline intelligence.
    Deb S; Dhaliwal AJ; Roy M
    J Intellect Disabil Res; 2008 Nov; 52(11):950-65. PubMed ID: 18179511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron Deficiency Parameters in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Percinel I; Yazici KU; Ustundag B
    Child Psychiatry Hum Dev; 2016 Apr; 47(2):259-69. PubMed ID: 26092605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between chronotype and obesity in children and adolescent with attention deficit hyperactivity disorder.
    Türkoğlu S; Çetin FH
    Chronobiol Int; 2019 Aug; 36(8):1138-1147. PubMed ID: 31177853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of neuropsychological performances and behavioral patterns of children with attention deficit hyperactivity disorder and severe mood dysregulation.
    Uran P; Kılıç BG
    Eur Child Adolesc Psychiatry; 2015 Jan; 24(1):21-30. PubMed ID: 24619769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADHD subtype-specific cognitive correlates and association with self-esteem: a quantitative difference.
    Molavi P; Nadermohammadi M; Salvat Ghojehbeiglou H; Vicario CM; Nitsche MA; Salehinejad MA
    BMC Psychiatry; 2020 Oct; 20(1):502. PubMed ID: 33046041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 levels in children with attention-deficit/hyperactivity disorder.
    Bilgiç A; Toker A; Işık Ü; Kılınç İ
    Eur Child Adolesc Psychiatry; 2017 Mar; 26(3):355-363. PubMed ID: 27561780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the French Version of Conners' Parent Rating Scale-Revised, Short Form in ADHD-Diagnosed Children and Comparison With Control Children.
    Fumeaux P; Mercier C; Roche S; Iwaz J; Stéphan P; Revol O
    J Atten Disord; 2021 Jan; 25(1):124-133. PubMed ID: 29562852
    [No Abstract]   [Full Text] [Related]  

  • 13. Exploratory study to evaluate plasma vasopressin and apelin-13 levels in children with attention-deficit hyperactivity disorder.
    Bilgiç A; Toker A; Uysal S
    Psychiatry Clin Neurosci; 2016 Oct; 70(10):442-447. PubMed ID: 27283127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent Validity of the Behavior Rating Inventory of Executive Function in Children With Attention Deficit Hyperactivity Disorder.
    Zarrabi M; Shahrivar Z; Tehrani Doost M; Khademi M; Zargari Nejad G
    Iran J Psychiatry Behav Sci; 2015 Mar; 9(1):e213. PubMed ID: 26251658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ubiquinone Levels as a Marker of Antioxidant System in Children with Attention Deficit Hyperactivity Disorder.
    Karagöz YS; Doğan Ö; Elgün S; Öztop DB; Kılıç BG
    J Mol Neurosci; 2021 Oct; 71(10):2173-2178. PubMed ID: 33245486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BDNF Val66Met polymorphism and peripheral protein levels in pediatric bipolar disorder and attention-deficit/hyperactivity disorder.
    Zeni CP; Tramontina S; Aguiar BW; Salatino-Oliveira A; Pheula GF; Sharma A; Stertz L; Moreira Maia CR; Hutz M; Kapczinski FP; Rohde LA
    Acta Psychiatr Scand; 2016 Sep; 134(3):268-74. PubMed ID: 27209073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid and Cortisol hormones in Attention Deficit Hyperactivity Disorder: A case-control study.
    Kuppili PP; Pattanayak RD; Sagar R; Mehta M; Vivekanandhan S
    Asian J Psychiatr; 2017 Aug; 28():73-77. PubMed ID: 28784401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondrial DNA copy number may be associated with attention deficit/hyperactivity disorder severity in treatment: a one-year follow-up study.
    Öğütlü H; Esin İS; Erdem HB; Tatar A; Dursun OB
    Int J Psychiatry Clin Pract; 2021 Mar; 25(1):37-42. PubMed ID: 33555215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleep disturbances and serum ferritin levels in children with attention-deficit/hyperactivity disorder.
    Cortese S; Konofal E; Bernardina BD; Mouren MC; Lecendreux M
    Eur Child Adolesc Psychiatry; 2009 Jul; 18(7):393-9. PubMed ID: 19205783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
    Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
    J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.